CD90-targeted lentiviral vectors for HSC gene therapy.

Humans Antigens, CD34 / genetics Genetic Therapy / methods Genetic Vectors / genetics Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells
CD90 HSC targeting HSCs VSVG gene therapy hematopoietic stem cells measles scFv single chain variable fragments surface-engineered viral vectors

Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
04 10 2023
Historique:
received: 27 02 2023
revised: 12 06 2023
accepted: 03 08 2023
pmc-release: 04 10 2024
medline: 9 10 2023
pubmed: 8 8 2023
entrez: 8 8 2023
Statut: ppublish

Résumé

Hematopoietic stem cell (HSC) gene therapy is currently performed on CD34

Identifiants

DOI: 10.1016/j.ymthe.2023.08.003 PMID: 37550965 PMC: PMC10556220
pubmed: 37550965
pii: S1525-0016(23)00435-5
doi: 10.1016/j.ymthe.2023.08.003
pmc: PMC10556220
pii:
doi:

Substances chimiques

Antigens, CD34 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2901-2913

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI135953
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL136135
Pays : United States

Informations de copyright

Copyright © 2023 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests S.R. is consultant to Forty-Seven Inc. (Gilead Sciences) and Ensoma Inc. H.P.K is or was a consultant to and has or had ownership interests with Rocket Pharmaceuticals, Homology Medicines, VOR Biopharma, and Ensoma Inc. H.P.K. has also been a consultant to CSL Behring and Magenta Therapeutics.

Références

Nat Commun. 2018 Mar 12;9(1):1029
pubmed: 29531262
Science. 2020 Sep 25;369(6511):1637-1643
pubmed: 32820060
Nucleic Acids Res. 2016 Jul 8;44(W1):W474-8
pubmed: 27131379
Nat Nanotechnol. 2018 Mar;13(3):214-219
pubmed: 29379205
Mol Ther. 2016 Aug;24(7):1237-46
pubmed: 27058824
Nat Methods. 2010 Nov;7(11):929-35
pubmed: 20935652
Mol Ther. 2022 Jun 1;30(6):2186-2198
pubmed: 35240320
Hum Gene Ther. 1999 Mar 1;10(4):545-57
pubmed: 10094198
Mol Ther. 2008 Aug;16(8):1427-36
pubmed: 18578012
J Virol. 2016 Oct 14;90(21):9766-9781
pubmed: 27558416
Expert Opin Biol Ther. 2018 Sep;18(9):959-972
pubmed: 30067117
Stem Cell Reports. 2017 Apr 11;8(4):977-990
pubmed: 28330619
Mol Ther Methods Clin Dev. 2020 Jul 15;18:679-691
pubmed: 32802914
Oncotarget. 2016 Jun 14;7(24):35894-35916
pubmed: 27145285
Nucleic Acids Res. 2015 Jan;43(Database issue):D413-22
pubmed: 25378316
World J Microbiol Biotechnol. 2012 Jan;28(1):381-6
pubmed: 22806814
Mol Ther. 2017 Sep 6;25(9):2163-2175
pubmed: 28663101
J Exp Med. 1993 May 1;177(5):1331-42
pubmed: 7683034
PLoS Pathog. 2015 Jul 06;11(7):e1004999
pubmed: 26147640
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W270-7
pubmed: 21624888
Cell. 2022 Jan 20;185(2):250-265.e16
pubmed: 35021064
PLoS One. 2012;7(10):e46667
pubmed: 23071609
Br J Haematol. 2015 Jun;169(6):868-78
pubmed: 25819405
Hum Gene Ther. 2021 Jan;32(1-2):113-127
pubmed: 32741228
Methods. 2020 Aug 1;180:45-55
pubmed: 32387313
Protein Eng Des Sel. 2015 Apr;28(4):93-106
pubmed: 25715658
Nat Methods. 2022 Apr;19(4):449-460
pubmed: 35396484
Mol Ther. 2015 Jan;23(1):63-70
pubmed: 25189742
Front Immunol. 2014 Feb 05;5:22
pubmed: 24600447
Nat Commun. 2017 Aug 30;8(1):389
pubmed: 28855514
Nat Commun. 2018 Oct 29;9(1):4493
pubmed: 30374059
Methods Mol Biol. 2017;1545:1-20
pubmed: 27943203
Sci Adv. 2020 Nov 18;6(47):
pubmed: 33208369
J Control Release. 2013 Dec 10;172(2):426-35
pubmed: 23770010
Front Oncol. 2017 Jun 26;7:127
pubmed: 28695108
Mol Ther. 2010 Apr;18(4):725-33
pubmed: 19997089
Nat Commun. 2020 Jun 26;11(1):3232
pubmed: 32591530
Sci Transl Med. 2017 Nov 1;9(414):
pubmed: 29093179
Hum Gene Ther Methods. 2018 Jun;29(3):146-155
pubmed: 29706115
Cell Stem Cell. 2007 Dec 13;1(6):635-45
pubmed: 18371405
Nucleic Acids Res. 2011 Nov;39(21):e143
pubmed: 21911364
Sci Transl Med. 2019 Jul 31;11(503):
pubmed: 31366580
Blood. 2008 Dec 15;112(13):4843-52
pubmed: 18812471
Cell Rep. 2013 May 30;3(5):1539-52
pubmed: 23707063
Blood Adv. 2017 Oct 24;1(23):2088-2104
pubmed: 29296856
Bone Marrow Transplant. 2003 Jan;31(1):17-22
pubmed: 12621502
Eur J Pharm Biopharm. 2016 Jul;104:30-41
pubmed: 27108267
J Virol. 2009 Jun;83(12):6234-46
pubmed: 19369333
Biomaterials. 2018 Jun;167:132-142
pubmed: 29571049

Auteurs

Kurt Berckmueller (K)

Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Justin Thomas (J)

Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Eman A Taha (EA)

Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Biochemistry, Ain Shams University Faculty of Science, Cairo 11566, Egypt.

Seunga Choo (S)

Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Ravishankar Madhu (R)

Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Greta Kanestrom (G)

Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Peter B Rupert (PB)

Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Roland Strong (R)

Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Hans-Peter Kiem (HP)

Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA. Electronic address: hkiem@fredhutch.org.

Stefan Radtke (S)

Stem Cell and Gene Therapy Program, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: sradtke@fredhutch.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › CD90-targeted lentiviral vectors for HSC gene therapy.
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes CD › Antigènes CD34 › CD90-targeted lentiviral vectors for HSC gene therapy.
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Génie génétique › Thérapie génétique › CD90-targeted lentiviral vectors for HSC gene therapy.
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Vecteurs génétiques › CD90-targeted lentiviral vectors for HSC gene therapy.
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › CD90-targeted lentiviral vectors for HSC gene therapy.
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système hématopoïétique › Cellules de la moelle osseuse › Cellules souches hématopoïétiques › CD90-targeted lentiviral vectors for HSC gene therapy.